BPMC Blueprint Medicines Corporation

84.06
+2.33  (+3%)
Previous Close 81.73
Open 82.79
Price To Book 6.96
Market Cap 4,128,655,235
Shares 49,115,575
Volume 449,709
Short Ratio
Av. Daily Volume 477,740

NewsSee all news

  1. This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival
  2. Deciphera stock surges on gastrointestinal cancer drug success
  3. Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
  4. The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund
  5. Edited Transcript of BPMC earnings conference call or presentation 1-Aug-19 12:30pm GMT

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initial data due 4Q 2019.
Avapritinib BLU-285 - PIONEER
Indolent and smoldering systemic mastocytosis (SM)
PDUFA date under priority review February 14, 2020.
Avapritinib BLU-285
PDGFRα driven Gastrointestinal stromal tumors (GIST)
Phase 1 China enrolment to commence mid-2019.
BLU-554
Advanced hepatocellular carcinoma (HCC)
Phase 3 trial planned 1H 2018.
BLU-285
Gastrointestinal stromal tumors (GIST) harboring a PDGFRα D842V
Phase 1 updated data at ASCO 2019 - 60% ORR in post-platinum RET-fusion NSCLC and 63% ORR in RET-mutant MTC patients. NDA filing due 1Q 2020.
BLU-667 - ARROW
RET-altered solid tumors
Phase 2 enrolment to be completed 2H 2019. NDA filing due 1Q 2020.
Avapritinib BLU-285 - PATHFINDER
Advanced Systemic mastocytosis (SM)
Phase 1 updated data June 15, 2019 - ORR 77%. NDA filing due 1Q 2020.
Avapritinib BLU-285 - EXPLORER
Advanced Systemic mastocytosis (SM)
Phase 3 enrolment to be completed 2H 2019.
Avapritinib - Voyager
Gastrointestinal stromal tumors (GIST)
Phase 2 trial to be initiated 4Q 2019.
BLU-782
Fibrodysplasia ossificans progressiva (FOP)
Phase 3 trial to be initiated 2H 2019.
Pralsetinib (BLU-667)
First-line RET-fusion non-small cell lung cancer (NSCLC)
Phase 2 trial to be initiated 2H 2019.
Pralsetinib (BLU-667) and osimertinib
EGFR-mutant non-small cell lung cancer (NSCLC)

Latest News

  1. This Biotech Is On A Two-Day Sprint; Why An Analyst Prefers Its Rival
  2. Deciphera stock surges on gastrointestinal cancer drug success
  3. Blueprint Medicines Announces FDA Acceptance of New Drug Application for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST
  4. The Top 5 Buys of the Eaton Vance Worldwide Health Sciences Fund
  5. Edited Transcript of BPMC earnings conference call or presentation 1-Aug-19 12:30pm GMT
  6. Blueprint Medicines to Present at 2019 Wedbush PacGrow Healthcare Conference
  7. 3 Lung Cancer Stocks That Could Soar in September
  8. Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark
  9. Blueprint Medicines (BPMC) Q2 2019 Earnings Call Transcript
  10. Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
  11. Blueprint Medicines Reports Second Quarter 2019 Financial Results
  12. Blueprint Medicines to Report Second Quarter 2019 Financial Results on Thursday, August 1, 2019
  13. 5 Biotech Stocks to Buy for a Strong Growth Prognosis
  14. Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application for Avapritinib for the Treatment of PDGFRα D842V Mutant GIST and Fourth-Line GIST
  15. 3 Soaring Biotech Stocks With More Fuel in the Tank
  16. Here's Why Blueprint Medicines Stock Rose 75% in the First Half of 2019
  17. Has Blueprint Medicines Corporation (NASDAQ:BPMC) Got Enough Cash?
  18. 2 Stocks That Could Be the Next Biotech Buyouts
  19. The Zacks Analyst Blog Highlights: Incyte, Blueprint Medicines, Verastem and uniQure
  20. See what the IHS Markit Score report has to say about Blueprint Medicines Corp.